The Chemours Company (NYSE:CC) Shares Purchased by First Trust Advisors LP

First Trust Advisors LP lifted its position in shares of The Chemours Company (NYSE:CC - Free Report) by 26.7% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 496,255 shares of the specialty chemicals company's stock after purchasing an additional 104,506 shares during the quarter. First Trust Advisors LP owned about 0.33% of Chemours worth $8,387,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Vanguard Group Inc. raised its holdings in shares of Chemours by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 15,223,961 shares of the specialty chemicals company's stock valued at $257,285,000 after buying an additional 94,885 shares during the period. Norges Bank purchased a new position in shares of Chemours in the fourth quarter valued at $30,702,000. American Century Companies Inc. increased its position in shares of Chemours by 7.6% during the fourth quarter. American Century Companies Inc. now owns 1,625,019 shares of the specialty chemicals company's stock worth $27,463,000 after acquiring an additional 115,436 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its stake in shares of Chemours by 4.4% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,593,070 shares of the specialty chemicals company's stock worth $26,923,000 after acquiring an additional 66,962 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Chemours by 6.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,302,272 shares of the specialty chemicals company's stock valued at $22,008,000 after purchasing an additional 73,220 shares during the last quarter. Institutional investors and hedge funds own 76.26% of the company's stock.

Chemours Stock Performance

CC traded up $0.27 during trading on Friday, reaching $12.47. 1,885,956 shares of the company were exchanged, compared to its average volume of 1,877,656. The Chemours Company has a 52 week low of $9.33 and a 52 week high of $29.21. The company has a current ratio of 1.68, a quick ratio of 0.92 and a debt-to-equity ratio of 6.70. The firm has a 50 day moving average of $12.94 and a 200 day moving average of $16.86. The stock has a market cap of $1.86 billion, a P/E ratio of 21.88 and a beta of 1.84.

Chemours (NYSE:CC - Get Free Report) last released its quarterly earnings results on Tuesday, February 18th. The specialty chemicals company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.10 by $0.01. The business had revenue of $1.36 billion during the quarter, compared to analyst estimates of $1.37 billion. Chemours had a net margin of 1.51% and a return on equity of 26.54%. On average, sell-side analysts forecast that The Chemours Company will post 2.03 EPS for the current fiscal year.

Chemours Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 14th. Stockholders of record on Friday, February 28th were given a dividend of $0.25 per share. The ex-dividend date was Friday, February 28th. This represents a $1.00 annualized dividend and a dividend yield of 8.02%. Chemours's dividend payout ratio is presently 175.44%.

Wall Street Analysts Forecast Growth

CC has been the topic of a number of recent analyst reports. Morgan Stanley cut their target price on Chemours from $25.00 to $22.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. Barclays reduced their price objective on shares of Chemours from $19.00 to $16.00 and set an "equal weight" rating on the stock in a research note on Tuesday, April 1st. The Goldman Sachs Group cut their target price on shares of Chemours from $24.00 to $21.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 7th. BMO Capital Markets decreased their price target on Chemours from $34.00 to $27.00 and set an "outperform" rating for the company in a research note on Wednesday, February 19th. Finally, Truist Financial cut their price objective on Chemours from $27.00 to $22.00 and set a "buy" rating on the stock in a research note on Monday, April 14th. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, Chemours currently has a consensus rating of "Moderate Buy" and a consensus price target of $21.56.

Chemours Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.